Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

23094 Breast Cancer Antigen (CA 27.29)

Breast Cancer Antigen (CA 27.29)
Test Code: CA2729
Synonyms/Keywords
Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 , (CA 27.29), MAM 6, Milk Mucin, CA 27-29
Useful For
The test is intended for use as aid in monitoring patients previously treated for Stage II or Stage III breast cancer.  Serial testing or CA27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence.  The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. 
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Serum​ ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​0.5 mL ​0.3 mL ​0.25 mL
Collection Processing Instructions
Serum gel tubes should be centrifuged within 2 hours of collection.  Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.  Tightly cap and refrigerate specimens at 2-8 degrees Celsius for storage and transport.  Freeze samples at or below -20 degrees Celsius if the sample is not assayed within 7 days.  Freeze samples only once and mix thoroughly after thawing. 
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Frozen (preferred) ​90 days
​Refrigerated 7 days
​Room Temperature 4 days
Rejection Criteria
Samples not meeting storage conditions
​Grossly icteric samples
Interference

​Heterophilic antiboies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.  Patients routinely exposed to animals or to animal serum products can be prone to this inteference and anomalous values may be observed.  Additional information may be required.

There are no known cross-reactants for CA 27.29.

Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Marshfield Monday,Wednesday, and Friday 60 minutes
Competitive Immunoassay using Direct Chemiluminometric Technology/Siemens Centaur XP
Reference Range Information
<=38.6 U/mL
Interpretation
Increased levels of CA 27.29 (>38 U/mL) may indicate recurrent disease in a woman with treated breast carcinoma.
 
Assay is not intended for use as a screening test or for diagnosis.
 
Normal levels of CA 27.29 as absolute evidence to the presence of the absence of malignant disease.
 
Before treatment, patients with confirmed breast carcinoma frequently have levels of CA 27.29 within the range observed in healthy individuals.  Additionally, elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases.
 
Measurements of CA 27.29 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
 
Exercise caution when interpreting CA 27.29 levels during pregnancy.
 
The concentration of CA 27.29 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.  CA 27.29 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
86300 ​ ​ ​ ​
Synonyms/Keywords
Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 , (CA 27.29), MAM 6, Milk Mucin, CA 27-29
Ordering Applications
Ordering Application Description
​Centricity ​Breast Ca Antigen (CA 27.29)
​Cerner Breast Ca Antigen (CA 27.29)
​COM Breast Ca Antigen (CA 27.29)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Serum​ ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​0.5 mL ​0.3 mL ​0.25 mL
Collection Processing
Serum gel tubes should be centrifuged within 2 hours of collection.  Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.  Tightly cap and refrigerate specimens at 2-8 degrees Celsius for storage and transport.  Freeze samples at or below -20 degrees Celsius if the sample is not assayed within 7 days.  Freeze samples only once and mix thoroughly after thawing. 
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Frozen (preferred) ​90 days
​Refrigerated 7 days
​Room Temperature 4 days
Rejection Criteria
Samples not meeting storage conditions
​Grossly icteric samples
Interference

​Heterophilic antiboies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.  Patients routinely exposed to animals or to animal serum products can be prone to this inteference and anomalous values may be observed.  Additional information may be required.

There are no known cross-reactants for CA 27.29.

Useful For
The test is intended for use as aid in monitoring patients previously treated for Stage II or Stage III breast cancer.  Serial testing or CA27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence.  The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. 
Reference Range Information
<=38.6 U/mL
Interpretation
Increased levels of CA 27.29 (>38 U/mL) may indicate recurrent disease in a woman with treated breast carcinoma.
 
Assay is not intended for use as a screening test or for diagnosis.
 
Normal levels of CA 27.29 as absolute evidence to the presence of the absence of malignant disease.
 
Before treatment, patients with confirmed breast carcinoma frequently have levels of CA 27.29 within the range observed in healthy individuals.  Additionally, elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases.
 
Measurements of CA 27.29 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
 
Exercise caution when interpreting CA 27.29 levels during pregnancy.
 
The concentration of CA 27.29 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.  CA 27.29 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Marshfield Monday,Wednesday, and Friday 60 minutes
Competitive Immunoassay using Direct Chemiluminometric Technology/Siemens Centaur XP
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
86300 ​ ​ ​ ​
For most current information refer to the Marshfield Laboratory online reference manual.